Introduction
============

Bone, a dynamic tissue, is remodeled by the balanced action of bone formation and bone resorption. Estrogen deficiency facilitates bone remodeling, resulting in enlargement of the remodeling space with increases in cortical porosity creating resorption areas on the trabecular surface. Excess bone resorption is primarily caused by increased osteoclastogenesis. The main action of estrogen is to reduce osteoclastogenesis ([@B31]). Osteoclasts (OC) are responsible for bone resorption. OC are derived from hematopoietic cells of the monocyte/macrophage lineage, sharing some morphological and functional characteristics with macrophages. There are two essential molecules required for osteoclastogenesis generated by bone marrow mesenchymal cells: macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor (TNF) family ([@B11]; [@B27]). The binding of RANKL to its receptor, RANK, induces and activates signaling pathways required for differentiation, including not only the generation of reactive oxygen species (ROS), but also the induction of nuclear factor in activated T-cells, cytoplasmic 1 (NFAT2) to initiate signals for OC differentiation ([@B2]). Activated transcription factors result in the expression of target genes, including tartrate resistant alkaline phosphatase (TRAP) and calcitonin receptor.

ROS participate in a signaling pathway of RANKL/RANK interaction. RANKL stimulation generates ROS in OC cells ([@B16]), which express NADPH oxidase, a ROS-generating enzyme ([@B26]). Since ROS play roles in OC differentiation and bone resorption, antioxidants are used therapeutically to protect against bone loss. Human studies have shown lowered levels of antioxidants in osteoporotic patients ([@B1]; [@B18]). The antioxidant N-acetylcysteine (NAC) reduces bone loss in post-menopausal women ([@B25]). In an animal model, ovariectomy (OVX) induces oxidative stress and results in bone loss. NAC and vitamin C reduces OVX-induced bone loss in mice ([@B14]).

Platinum, a harmless metal, is widely used in a variety of industrial products, because of its catalytic activity. Since nanoparticles have unique chemical and biological properties, they are expected to have considerable potential in a wide range of biomedical applications. Their small sizes provide large surface areas on the nanometric scale, increasing their reactivity. Platinum nanoparticles (PtNP) eliminate anion radicals and hydrogen peroxide in a manner similar to superoxide dismutase and catalase ([@B6]; [@B30]), suggesting a role as an antioxidant.

In the present study, we investigated whether PtNP have therapeutic effects in OVX-induced bone loss through their action on osteoclastogenesis.

Results
=======

PtNP protects against OVX-induced bone loss
-------------------------------------------

The femoral bone density of PtNP-administered mice was significantly higher than that of vehicle-treated mice after OVX, especially the distal metaphysis of the femur ([Figures 1A](#F1){ref-type="fig"} and [2B](#F2){ref-type="fig"}; *P* \< 0.01). There were no significant differences between groups after sham surgery. Consistent with this finding, the PtNP-treated OVX mice had reduced levels of serum collagen-type I fragments (CTX-1), which is a bone resorption marker ([Figure 1C](#F1){ref-type="fig"}; *P* \< 0.001). PtNP also decreased serum TRACP5b due to OVX ([Figure 1D](#F1){ref-type="fig"}; *P* \< 0.05). However, the serum marker of bone formation, N-terminal propeptide of type I procollagen (PINP) was not significantly affected by PtNP treatment in OVX mice ([Figure 1E](#F1){ref-type="fig"}). OVX also increased body weight compared to sham surgery (sham, 6.60 ± 0.50 g vs. OVX, 12.02 ± 0.53 g; *P* \< 0.001), and PtNP treatment reduced this elevation of body weight in OVX mice (7.82 ± 0.45 g; *P* \< 0.001), showing that the elevation of bone mass by PtNP was not due to any increase of body mass.

PtNP decreases OC formation
---------------------------

To elucidate the mode of action of the PtNP on bone metabolism, we assessed its effect on BMM, which are OC precursors. PtNP inhibited OC formation from BMM in a dose-dependent manner ([Figures 2A and 2B](#F2){ref-type="fig"}), while total cell numbers were not significantly affected (data not shown), suggesting that the inhibitory effect was not due to cytotoxicity. Consistent with this result, transcripts of TRAP, calcitonin receptor, and cathepsin K were significantly reduced after RANKL stimulation of BMM in the presence of PtNP ([Figure 2C](#F2){ref-type="fig"}). These results suggest that PtNP inhibit OC differentiation by acting in BMM.

During the differentiation of OCs, RANKL induces a key transcription factor, NFAT2, which plays critical and specific roles ([@B29]). We examined whether PtNP affect the activation of these RANKL-induced signaling pathways. The exposure of BMM to RANKL resulted in induction of NFAT2. The expression level of NFAT2 in BMM after 48 hrs of RANKL stimulation was greatly reduced in the presence of PtNP ([Figure 3A](#F3){ref-type="fig"}). We also examined RANKL-induced NFAT2 expression by immunofluorescence staining using an anti-NFAT2 Ab ([Figure 3B](#F3){ref-type="fig"}). In the absence of RANKL, almost no NFAT2 staining was detectible (first row), while in response to RANKL the expression of NFAT2 was found in the nucleus as well as in the cytoplasm. NFAT2 was superimposed in multinucleated cells characteristic for mature OC (second row). By contrast, treatment with PtNP resulted in not only a lowered number of OC, but also an attenuated level of NFAT2 expression in comparison to vehicle treatment (second vs. third row).

Since ROS mediate RANKL signaling associated with NFAT2 activation in OC ([@B9]), we tested whether PtNP affected RANKL-induced ROS generation. RANKL stimulated the formation of substantial levels of ROS in BMM, and again exogenous PtNP opposed this effect ([Figure 3C](#F3){ref-type="fig"}). This finding implies that the reduction of osteoclastogenesis by PtNP could be due to decreased ROS production in response to RANKL.

Since ROS induces long lasting \[Ca^2+^\]~i~ oscillations necessary for OC formation ([@B9]), we also evaluated whether PtNP reduced RANKL-induced \[Ca^2+^\]~i~ oscillations. Long term activation of BMM with RANKL for 48 hrs induced the increase in the total \[Ca^2+^\]~i~, whereas PtNP significantly attenuated it as shown in [Figure 3D](#F3){ref-type="fig"}. Furthermore, the amplitude and frequency of \[Ca^2+^\]~i~ oscillation response of each cell was also reduced by PtNP ([Figure 3E](#F3){ref-type="fig"}).

To investigate further inhibitory mechanism of PtNP in OC, we examined whether PtNP affected the RANKL-induced nuclear factor-κB (NF-κB) activation. As shown in [Figure 3F](#F3){ref-type="fig"}, crosslinking of RANKL to RANK stimulated NF-κB DNA binding activity (lane 5), and PtNP decreased this effect in a dose-dependent manner (lane 3, 4). The specific binding was confirmed by competition assay using mutant competitor probes (lane 1).

Since RANKL binding to RANK activates three mitogen-activated protein kinases (MAPK) and Akt ([@B17]), we also examined whether PtNP affected the activation of these MAPKs and Akt. RANKL activated all 4 kinases in 5-15 min as shown in [Figure 3G](#F3){ref-type="fig"}. PtNP attenuated activation of p38 at a modest degree, but not significant decrease in that of ERK, JNK, and Akt.

Taken together, our data indicate that PtNP caused defective RANKL signaling by decreased NFAT2 expression as well as impaired NF-κB activation.

Discussion
==========

We demonstrated that exposure to PtNP reduced OVX-induced bone loss *in vivo*. PtNP opposed not only substantial reduction in femoral bone density, but also the elevation of CTX-1 and TRACP5b observed after OVX. Although OVX also increased body weight dramatically ([@B10]), PtNP protected against this effect, so eliminating the possibility that the elevated bone mass is not due to increased body mass. The mechanism by which PtNP reduce the increase in body weight following OVX is now under investigation.

Bone is a dynamic tissue, involving a balance between bone formation by osteoblasts and resorption by OC ([@B3]). Postmenopausal osteoporosis may represent an imbalance in the favor of bone resorption over bone formation ([@B24]). Higher bone density facilitated by PtNP after OVX appears to be due to inhibition of osteoclastogenesis. OCs are primarily responsible for bone resorption, and PtNP substantially inhibit OC formation. Gold nanoparticles suppressed the NF-κB activation and reduced the ROS level ([@B28]). Rutin acted as an antioxidant in OC to inhibit osteoclastogenesis *via* decreased the NF-κB activation ([@B12]). Similar pattern was observed with PtNP-induced inhibitory effect in OC.

PtNP inhibit RANKL-induced OC formation *in vitro* by impairing RANKL signaling. PtNP did not display cytotoxicity to the BMM under these conditions. RANKL, a key differentiation factor for OC, is reported to induce the production of ROS ([@B9]), indicating that ROS may take part in OC differentiation. We showed that PtNP attenuated ROS production and the total \[Ca^2+^\]~i~ and \[Ca^2+^\]~i~ oscillation stimulated by RANKL, and significantly decreased the expression of NFAT2. NFAT2 is an integral component of the RANKL signalling pathway during OC differentiation. RANKL induces the expression and activation of NFAT2. Deficiencies of NFAT2 result in failure of OC differentiation, indicating that NFAT2 is a master switch controlling terminal differentiation of OCs ([@B29]). A series of RANKL-induced signals leads to oscillation in the free \[Ca^2+^\]~i~, which triggers the later stage of OC differentiation by autoamplification of NFAT2 ([@B29]). RANKL causes a long lasting increase in ROS and \[Ca^2+^\]~i~ that is critical for OC differentiation ([@B9]), suggesting that ROS may be responsible for the expression and the activation of NFAT2 on RANKL stimulation. Since PtNP decrease ROS, this decrease could be directly associated with decreased expression of NFAT2, consequently resulting in decreased NFAT2 activity. Blockade of NFAT activation by antioxidants has been demonstrated in several other cell types. NAC and catalase prevent vanadium-induced NFAT activation mediated by H~2~O~2~ in fibroblasts ([@B5]), and adenovirally over-expressed Gpx-1 or manganese superoxide dismutase inhibits doxorubicin-induced nuclear NFAT translocation in rat cardiac cells ([@B7]).

Our data indicate that PtNP act as antioxidants in OC and protect oxidative stress induced by OVX. This result is consistent with other findings that have demonstrated that the metal nanoparticle catalyzes some redox reactions. While we were preparing this, PtNP has been reported to decrease ROS *via* attenuating ROS-producing NOX family oxidases, NOX1 and NOX4, resulting in reduced osteoclasto-genesis ([@B21]). PtNP significantly inhibits heat-induced apoptosis in a dose-dependent manner. Superoxide has been suppressed to various extents ([@B32]). The PtNP complementarily stabilized with pectin decomposes hydrogen peroxide and consequently generate oxygen like catalase ([@B6]). PtNP significantly extends the lifespan of wild-type nematodes and recovers the shortened lifespan of the mutant, which has excessive oxidative stress by acting as a superoxide dismutase/catalase mimetic ([@B8]). The potential use of PtNP as antioxidants calls for consideration of their possible biological toxicity. The cytotoxicity of PtNP has not been studied, but gold nanoparticles were nontoxic to mice and humans ([@B20]; [@B22]). Nanonization affects saturation solubility as well as surface area, increasing efficiency of delivery. It allows nanoparticles to reach high concentrations in tumors, and enhances the efficacy of X-ray therapy ([@B4]). In therapeutic usage, the nonspecific uptake by macrophages could be a problem, due to the removal of more than 90% of an injected dose in 5 min ([@B19]). However, the transport of PtNP may not be a problem in OC whose precursor are macrophages. Our findings provide a rationale for the protective effect of PtNP on post menopause-associated bone loss. Further studies could lead to the use of PtNP in a novel therapy for osteoporosis.

Methods
=======

Animals and study design
------------------------

Six-week-old C57BL/6J mice purchased from the Jackson Laboratory, and cared for at the University of Ulsan Immunomodulation Research Center (IRC) were subjected to OVX (*n* = 13) or sham operation (*n* = 11). PtNP were prepared every day as a solution of 200 µg/ml in phosphate-buffered saline (PBS). After surgery, vehicle (*n* = 12) or a solution of platinum nanoparticles (5 µg/g of body weight/day) (*n* = 12) was given intragastrically (0.5 ml/each) through an esophageal cannula to ensure delivery of the correct dose daily for 8 weeks. Bone density was analyzed. All mice were housed in the specific pathogen-free animal facility of the IRC and were handled in accordance with the guidelines of the Institutional Animal Care and Use Committee of the IRC. The standards were approved by that Committee (2010-021). Radiographic analysis of the femora was performed with a soft X-ray system (model CMB-2). The relative bone density of the distal metaphysis of the femur was measured by X-ray radiographic analysis with a real time image processing and measurement system (ZET-1). The accuracy and precision of these measurements were evaluated previously ([@B13]). The femora of each animal were removed and preserved in 10% neutral buffered formalin. Bone remodeling marker was measured according to the manufacturer\'s directions (Immunodiagnostic Systems Inc.): serum collagen-type I fragments (CTX-1) by RatLaps EIA, serum TRACP 5b by solid phase immunofixed enzyme activity assay, and N-terminal propeptide of type I procollagen (PINP) by a competitive EIA.

OC formation
------------

Bone marrow cells were isolated from 4-5-week-old C57BL/6J mice as described ([@B15]). Femora and tibiae were removed aseptically and dissected free of adherent soft tissues. The bone ends were cut away, and the marrow cavity was flushed out from one end of the bone with α-modified minimum essential medium (α-MEM) using a sterile 21-gauge needle. The bone marrow suspension was carefully agitated with a plastic Pasteur pipette to obtain single cells. These cells were washed twice and resuspended in α-MEM containing 10% fetal bovine serum (FBS), and the suspension was incubated on plates along with M-CSF (20 ng/ml) (R & D Systems, Inc., Minneapolis, MN) for 16 h. Non-adherent cells were then harvested, and cultured with M-CSF for two more days, at which time large populations of adherent monocyte/macrophage-like cells had formed on the bottom of the culture plates. The small number of non-adherent cells was removed by rinsing the dishes with PBS. The remaining adherent bone marrow-derived macrophages (BMM) were harvested and seeded in plates. Additional medium containing M-CSF and RANKL (40 ng/ml) (R & D Systems, Inc.) was added, and the medium was replaced on day 3. After incubation for the indicated times, the cells were fixed in 10% formalin for 10 min, and stained for TRAP as described ([@B15]). The number of TRAP-positive multinucleated cells (MNC) (three or more nuclei) was scored.

PtNP
----

The PtNP were prepared by a novel single-step method ([@B23]). The electrical explosion of platinum wire (3 kV of charging voltage for 0.1 mm wire) in distilled water results in a highly dispersed suspension of PtNP with -12.62 mV of zeta potential. The average size of the platinum nanoparticles was found to be (\> 100) nm by using field emission scanning electron microscopy. The PtNP were sterilized under UV light for 1day, and adjusted to 5-20% (v/v) α-MEM when treated.

Quantitative PCR (qPCR)
-----------------------

Total RNA isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA) was reverse-transcribed with oligo-dT and Superscript I enzyme (Invitrogen), according to the manufacturer\'s instructions. Quantitative RT-PCR was carried out using SYBR Green 1 *Taq* polymerase (Qiagen, Hilden, Germany) and appropriate primers on a DNA Engine Opticon Continuous Fluorescence detection System (MJ Research Inc., Waltham, MA). The specificity of each primer pair was confirmed by melting curve analysis and agarose-gel electrophoresis. The housekeeping GAPDH gene was amplified in parallel with the genes of interest. The relative copy numbers compared to GAPDH were calculated using the expression 2^-ΔΔCt^. The primer sequences used were as follows: 5\'-ctgctcctagtgagcccaac-3\' and 5\'-cagcaatcgacaaggagtga-3\' (calcitonin receptor); 5\'-gaccaccttggcaatgtctctg-3\' and 5\'-tggctgaggaagtcatctgagttg-3\' (TRAP);, 5\'-tgaggcttctcttggtgtccatac-3\' and 5\'aaagggtgtcattactgcggg-3\' (cathepsin K); 5\'-aataacatgcgagccatcatc-3\' and 5\'-tcaccctggtgttcttcctc-3\' (NFAT2); 5\'-acccagaagactgtggatgg-3\' and 5\'-cacattgggggtaggaacac-3\' (GAPDH).

Expression of NFAT2
-------------------

The BMM were incubated on culture plates with M-CSF with or without RANKL for 72 h to generate OCs. The cells were fixed in 10% neutral buffered formalin and permeabilized with 0.1% Triton X-100. Immunofluorescence staining was performed using mouse anti-NFAT2 Ab (Santa Cruz Biotechnology) followed by FITC-conjugated anti-mouse IgG (eBioscience) and Hoechst (Sigma Chemical, St. Louis, MO). The subcellular localization of FITC-labeled NFAT2 was examined using a fluorescence microscope (Carl Zeiss, Germany).

Intracellular reactive oxygen species (ROS) detection
-----------------------------------------------------

The intracellular formation of ROS was detected using the fluorescence probe, 2\', 7\'-dichlorofluorescein diacetate (DCFH-DA) (Molecular Probe). After the BMM were cultured under the different experimental conditions for 48 h, the cells were harvested, trypsinized, suspended in PBS, loaded with DCFH-DA, and incubated at 37℃ for 30 min. The measurement of intracellular ROS was performed using a flow cytometry with a fluorescence-activated cell sorter (FACS) Calibur (Becton Dickinson).

Intracellular concentration of Ca^2+^ (\[Ca^2+^\]~i~)
-----------------------------------------------------

BMM were incubated with RANKL and M-CSF for 48 h. For \[Ca^2+^\]~i~ measurement, cells were incubated with 5 µM fluo-4 AM, 5 µM Fura Red AM, and 0.05% pluronic F127 for 30 min in serum-free DMEM as described ([@B29]). Cells were incubated further with M-CSF for 20 min, and analyzed using a confocal microscope (Olympus). To estimate \[Ca^2+^\]~i~ in single cells, the ratio of the fluorescence intensity of fluo-4 to fura red was calculated. The increase in the ratio from the basal level was divided by the maximum ratio increase obtained by adding 10 µM ionomycin and was expressed as the % maximum ratio increase. For measurement of total \[Ca^2+^\]~i~ BMM cultured with RANKL and M-CSF for 48 h were loaded with fluo-4 at 37℃ for 30 min, further incubated at room temperature for additional 30 min, and analyzed with an excitation/emission filter pair (488/530 nm).

EMSA
----

BMM were stimulated with RANKL for 1 h and nuclear extracts were prepared. NF-κB-binding studies were performed using a double-stranded oligonucleotide (Santa Cruz Biotechnology, San Diego, CA) containing an NF-κB consensus binding site. The oligonucleotide or a variant was end-labeled with \[γ-^32^P\]ATP using T4 polynucleotide kinase (Promega, Madison, WI). Five µg of each nuclear extract was incubated at 30℃ for 20 min with 1 ng of ^32^P-labeled probe in 10 µl of binding buffer containing 1 µg of poly (dI.dC), 15 mM HEPES, pH 7.6, 80 mM NaCl, 1 mM EGTA, 1 mM dithiothreitol, and 10% glycerol. DNA-protein complexes were visualized by electrophoresis on a native 5% polyacrylamide gel, vacuum-drying and autoradiography using an intensifying screen at -80℃.

Western blotting
----------------

Blots were probed with Abs against phosphorylated form of ERK, JNK, p38, and Akt (Cell Signaling) or β-actin (Santa Cruz Biotech.), and then incubated with the corresponding peroxidase-conjugated secondary Ab (Santa Cruz Biotech.).

Statistical analysis
--------------------

All values are expressed as means ± SEM. Student\'s *t*-test was used to evaluate differences between samples of interest and the corresponding controls. Differences between groups were assessed by two-way ANOVA followed by Bonferroni post tests. A probability (*P*) value of less than 0.05 was considered statistically significant.

This work was supported by grants from the National Research Foundation funded by the Korean government (BRL-2009-0087350; KRF-2010-0002644).

BMM

:   bone marrow-derived macrophages

\[Ca^2+^\]~i~

:   intracellular concentration of Ca^2+^

CTX-1

:   collagen-type I fragments

DCFH-DA

:   2\',7\'-dichlorofluorescein diacetate

M-CSF

:   macrophage-colony stimulating factor

MNC

:   multinucleated cells

NAC

:   N-acetylcysteine

NFAT2

:   nuclear factor of activated T-cells cytoplasmic 1

OC

:   osteoclast

OVX

:   ovariectomy

PtNP

:   platinum nanoparticles

RANKL

:   receptor activator of nuclear factor-κB ligand

ROS

:   reactive oxygen species

TRAP

:   tartrate resistant alkaline phosphatase

![The effects of PtNP on OVX-induced bone loss in mice. The relative intensities of the distal metaphysic of the femur from X-ray radiograms (A) from vehicle (open bar) (OVX, *n* = 6; sham, *n* = 6), platinum nanoparticle-treated (closed bar) (OVX, *n* = 7; sham, *n* = 5) mice, 8 wk after OVX and sham surgery were measured using Image J program (B). Serum CTX-1 (C), TRACP5b (D). N-terminal propeptide of type I procollagen (PINP) (E) were measured by ELISA. Data were mean + SEM. ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001 compared with vehicle-treated mice. Differences between groups were analyzed by two-way ANOVA, followed by Bonferroni post tests to compare the effect of PtNP. There was no significant difference of serum PINP levels between vehicle- and PtNP-treated OVX.](emm-44-432-g001){#F1}

![The effect of PtNP on RANKL-induced OC formation. BMMs (8 × 10^3^ cells/well) were prepared and incubated with PtNP (0, 10, 20, 40 µg/ml) in the presence of M-CSF (20 ng/ml) and RANKL (40 ng/ml). After 3 days, cells were fixed and stained for TRAP, and photographed. The number of TRAP-positive MNC per well was scored. ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001 compared with vehicle (A). Representative photos of A. Scale bar; 100 µm (B). BMMs (5 × 10^5^ cells/well) were incubated for 48 h with PtNP (40 µg/ml) in the presence of M-CSF and RANKL. Total RNA was isolated and subjected to qPCR analysis for TRAP, calcitonin receptor, and cathepsin K. The expression level before RANKL treatment was set at 1. ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001 compared with vehicle (C).](emm-44-432-g002){#F2}

![Impaired RANKL signaling by PtNP. BMM were stimulated with RANKL (40 ng/ml) and M-CSF (20 ng/ml) in the absence or presence of PtNP (40 µg/ml) for 48 hrs, and total RNA was extracted and subjected to qPCR analysis. The expression level before RANKL treatment was set at 1. ^\*^*P* \< 0.05 compared with vehicle (A). BMM were incubated for 72 hrs in the presence of M-CSF only (first row) and M-CSF+RANKL (second row). When multinucleated cells with the morphologic features of OCs were observed, the cells were stained with Hoechest (first column) and anti-NFAT2 Ab (second column) to identify nuclear translocation. RANKL treatment induced multinucleated cells whose nucleus were superimposed with NFAT2 (second, third row), whereas OC precursors showed little staining of NFAT2 (first row). PtNP reduced the number of multinucleated cells with reduced level of NFAT2 staining (second vs. third row). Scale bar, 100 µm (B). Intracellular levels of ROS upon stimulation with RANKL or RANKL + PtNP (40 µg/ml) in the presence of M-CSF for 48 hrs were determined in BMM cells using DCFH-DA. ROS levels were quantified by flow cytometry (C). Cells were loaded with fluo-4 AM for fluorescence (D). Cells were loaded with fluo-4 and Fura Red, and estimated as the ratio of fluorescence intensity of fluo-4 to Fura Red, and % maximum ratio increase from the base line was plotted with an interval of 5 sec. Maximum ratio increase was obtained with the addition of 10 µM ionomycin at the end of each experiment, indicated by an arrow. Each line indicated a different cell in the same field (E). BMM were stimulated with vehicle V (lane 2), or RANKL (lane 5) in the absence or presence of PtNP (20 µg/ml, lane 4; 40 µg/ml, lane 3) for 1 h. A variant NF-κB (lane 1) was used as a negative control (F). Cytokine- and serum-starved BMM were exposed to RANKL (60 ng/ml). Phosphorylated forms of p38, ERK, JNK, and Akt were detected by Western blots (G). (A color figure can be viewed in the online version, which is available at [www.e-emm.org](http://www.e-emm.org)).](emm-44-432-g003){#F3}
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